高危III期黑色素瘤完全切除后帕博利珠单抗复发患者的交叉治疗与再挑战
基于EORTC 1325/KEYNOTE-054 III期试验,分析安慰剂组复发后交叉接受帕博利珠单抗及帕博利珠单抗组完成1年辅助治疗后复发再挑战的患者。交叉组中位PFS 8.5个月,3年PFS率32%,可评估IV期患者ORR 39%;再挑战组中位PFS 4.1个月,可评估IV期患者ORR 11%。
要点
- 交叉组中位PFS 8.5个月,3年PFS率32%。
- 交叉组可评估IV期患者ORR 39%,其中CR 18%。
- 再挑战组中位PFS 4.1个月,可评估IV期患者ORR 11%。
核心结论
- 交叉接受帕博利珠单抗治疗3年PFS率为32%,可评估患者ORR为39%。
- 再挑战患者疗效较低,ORR为11%。
研究设计与样本
- III期双盲EORTC 1325/KEYNOTE-054试验,患者随机接受帕博利珠单抗200 mg(N=514)或安慰剂(N=505)每3周静脉给药,最长1年。
- 复发后可进入第二部分:帕博利珠单抗200 mg每3周静脉给药最长2年,交叉组为安慰剂组复发患者,再挑战组为完成1年辅助帕博利珠单抗治疗后≥6个月复发患者。
主要发现
- 交叉组中位PFS为8.5个月(95%CI 5.7-15.2),3年PFS率为32%(95%CI 25-40%)。
- 交叉组80例可评估IV期患者中31例(39%)客观缓解:14例(18%)完全缓解,17例(21%)部分缓解;缓解后2年PFS率为69%(95%CI 48-83%)。
- 再挑战组中位PFS为4.1个月(95%CI 2.6-NE);9例可评估IV期患者中1例客观缓解(CR)。
- 175例患者中51例(29%)发生I-IV级irAE,11例(6%)发生III-IV级irAE。
临床怎么用
- 高危III期黑色素瘤完全切除后复发患者可考虑帕博利珠单抗交叉治疗。
- 完成辅助帕博利珠单抗后复发再挑战的疗效较低,需权衡获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase III double-blind European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 trial, pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with stage III cutaneous melanoma with complete resection of lymph nodes. In the pembrolizumab group, the incidence of grade I-V and of grade III-V immune-related adverse events (irAEs) was 37% and 7%, respectively. METHODS: Patients were randomised to receive intravenous (i.v.) pembrolizumab 200 mg (N = 514) or placebo (N = 505) every 3 weeks, up to 1 year. On recurrence, patients could enter part 2 of the study: pembrolizumab 200 mg i.v. every 3 weeks up to 2 years, for crossover (those who received placebo) or rechallenge (those who had recurrence ≥6 months after completing 1-year adjuvant pembrolizumab therapy). For these patients, we present the safety profile and efficacy outcomes. RESULTS: At the clinical cut-off (16-Oct-2020), in the placebo group, 298 patients had a disease recurrence, in which 155 (52%) crossed over ('crossover'). In the pembrolizumab group, 297 patients completed the 1-year treatment period; 47 had a recurrence ≥6 months later, in which 20 (43%) entered the rechallenge part 2 ('rechallenge'). In the crossover group, the median progression-free survival (PFS) was 8.5 months (95% confidence interval [CI] 5.7-15.2) and the 3-year PFS rate was 32% (95% CI 25-40%). Among 80 patients with stage IV evaluable disease, 31 (39%) had an objective response: 14 (18%) patients with complete response (CR) and 17 (21%) patients with partial response. The 2-year PFS rate from response was 69% (95% CI 48-83%). In the rechallenge group, the median PFS was 4.1 months (95% CI 2.6-NE). Among 9 patients with stage IV evaluable disease, 1 had an objective response (CR). Among the 175 patients, 51 (29%) had a grade I-IV irAE and 11 (6%) had a grade III-IV irAE. CONCLUSIONS: Pembrolizumab treatment after crossover yielded an overall 3-year PFS rate of 32% and a 39% ORR in evaluable patients, but the efficacy (11% ORR) was lower in those rechallenged.
引用
- Eggermont AM, Meshcheryakov A, Atkinson V, et al. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. Eur J Cancer. 2021. PMID: 34678677. doi:10.1016/j.ejca.2021.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。